Given the intuitive potential of stem cell therapy and limitations of current treatment options for progressive multiple sclerosis (MS), it is not surprising that patients consider undertaking significant clinical and financial risks to access stem cell transplantation. However, while increasing evidence supports autologous haematopoietic stem cell transplantation (AHSCT) in aggressive relapsing–remitting MS, interventions employing haematopoietic or other stem cells should otherwise be considered experimental and recommended only in the context of a properly regulated clinical study. Understandably, most neurologists are unfamiliar with AHSCT procedures and the specific requirements for quality assurance and safety standards, as well as post-procedure precautions and follow-up. Consequently they may feel ill-equipped to advise patients. Here, we highlight important points for discussion in consultations with patients considering stem cell ‘tourism’ for MS.
- multiple sclerosis
- stem cells
- cell therapy
- haematopoietic stem cell transplanation
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors All authors contributed to the text. BvW designed the graphic.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests Not declared.
Patient consent Not required.
Provenance and peer review Not commissioned. Externally reviewed by Alasdair Coles, Cambridge, UK.
Read the full text or download the PDF:
Other content recommended for you
- Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis
- Autologous haematopoietic stem cell transplantation for neurological diseases
- Haematopoietic stem cell transplantation in systemic sclerosis
- Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
- Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP
- Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
- Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation
- Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?
- Current outlook of cardiac stem cell therapy towards a clinical application
- Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation